Sun Pharma Baska facility gets OAI status from USFDA
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-12-18 08:57 GMT | Update On 2025-12-18 08:57 GMT
Advertisement
Mumbai: Sun Pharma has announced that the company has received Official Action Indicated (OAI) status from the U.S. Food and Drug Administration (USFDA) for Baska facility.
The USFDA conducted an inspection at the facility from 8 September 2025 to 19 September 2025.
OAI means regulatory and/or administrative actions are recommended.
"We continue to manufacture and supply approved products from the facility to the US market. We will work with the regulator to achieve fully compliant status," the company stated in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.